Showing Results for: “Glycemic Index and Diabetes”

Today, the American Diabetes Association ® (ADA) published updates to the Standards of Care in Diabetes—2023 (Standards of Care) on the use of teplizumab in delaying the onset of type 1 diabetes. Type 1 diabetes is a chronic autoimmune disease that affects millions of people worldwide, and its incidence is increasing. Teplizumab is a monoclonal antibody that targets the immune system and has been shown to delay the onset of type 1 diabetes in high-risk individuals. The updated recommendations reflect recent clinical trial results and U.S. Food and Drug Administration (FDA) approval of

New guidelines include updates to recommendations around obesity, hypertension, heart failure medication, social determinants of health, and lipid management Today, the American Diabetes Association ® (ADA) published Standards of Care in Diabetes—2023 (Standards of Care) , comprehensive, evidence-based guidelines for the prevention, diagnosis, and treatment of diabetes. Based on the latest scientific research and clinical trials, the Standards of Care includes vital new and updated practice guidelines to care for people with diabetes and prediabetes, including for the diagnosis and treatment

Learn about the different classes of non-insulin medications used to lower blood glucose levels. Explore options like Metformin, DPP-4 inhibitors, GLP-1, and more.